FGFR2 and cholangiocarcinoma: The authors of a study evaluating seven patients with FGFR2-fusion-positive cholangiocarcinoma using the ultra-deep ctDNA panel Memorial Sloan Kettering-Analysis of Circulating Cell-free DNA to Evaluate Somatic Status (MSK-ACCESS) reported the detection of 19 acquired point mutations across five patients who progressed on targeted FGFR therapy.50 In summary, these preliminary studies suggest that gene fusions are harder to accurately detect than SNVs and amplifications using existing ctDNA assays.